Your browser doesn't support javascript.
loading
Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy.
Kang, Hae Min; Hasanuzzaman, Md; Kim, So Won; Koh, Hyoung Jun; Lee, Sung Chul.
Affiliation
  • Kang HM; Quantitative method, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Hasanuzzaman M; Catholic Kwandong University College of Medicine, Incheon, Republic of Korea.
  • Kim SW; Department of Pharmacology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Koh HJ; Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Lee SC; Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
PLoS One ; 17(5): e0268353, 2022.
Article in En | MEDLINE | ID: mdl-35544533
ABSTRACT

PURPOSE:

Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR.

METHODS:

A total 85 subjects were included in this prospective study. Those were classified into three groups advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group.

RESULTS:

Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0-21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6-2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7-3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0-20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0-21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3-4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0-7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively).

CONCLUSION:

The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cataract / Diabetes Mellitus / Diabetic Retinopathy Type of study: Observational_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cataract / Diabetes Mellitus / Diabetic Retinopathy Type of study: Observational_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Document type: Article Affiliation country:
...